SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Eightco Holdings, Inc. is a publicly traded holding company, which operates in the consumer products and e-commerce markets, focusing on developing and deploying innovative technology, and capital solutions to empower small to medium-sized businesses. It operates through the North America and Europe geographical segments. The company was founded in 1966 and is headquartered in Easton, PA.

Eightco Holdings Inc

Eightco Holdings ($OCTO) is trending due to a significant private placement announcement and a strategic investment related to launching a Worldcoin treasury strategy, sparking a massive pre-market surge and short squeeze. The community is actively discussing the potential for further gains, with some drawing comparisons to other high-flying stocks and speculating on how high it can go, while others caution about potential dilution risks. News of Dan Ives joining as Chairman seems to be adding fuel to the fire.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

ASTS is trending due to a mix of factors, including recent news of SpaceX acquiring spectrum, sparking concerns about increased competition, and the overall volatility in space stocks. The community is debating whether this validates ASTS's technology or poses a significant challenge. Bullish investors view it as a buying opportunity, while bears express concerns about dilution and the company's ability to compete.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending after a live demo of its solid-state batteries powering a Ducati motorcycle at the IAA Mobility event, sparking enthusiasm among investors. The community is buzzing about the potential for the technology in EVs and motorcycles, along with possible partnerships with major automotive manufacturers. Despite a long timeline to commercialization, some believe the demonstration validates the long-term potential of solid-state battery technology.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as it joins the S&P 500, replacing Caesars Entertainment, which has sparked enthusiasm and predictions of significant inflows from index funds. While some traders are wary of a potential "sell the news" event, others anticipate further gains fueled by the upcoming company summit and potential rate cuts. Community members are actively discussing potential price targets and the impact of index inclusion on the stock's long-term value.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as investors discuss its potential S&P 500 inclusion, with community members analyzing technical levels and anticipating a breakout. Bullish sentiment is fueled by the company's strong performance and perceived undervaluation compared to peers. Some traders express caution, citing potential overvaluation and historical patterns after index additions.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs ($PL) is trending due to strong Q2 FY2026 earnings, including record revenue and positive adjusted EBITDA, leading to raised full-year guidance. The community is actively discussing the significant increase in backlog and remaining performance obligations, viewing it as a sign of strong sales execution. Despite the positive news, some traders are questioning why the stock is not performing better, while others are optimistic about a potential rerating and further gains.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics (MCRB) is trending amid rumors of a potential acquisition by Nestle, with community members closely watching for confirmation and speculating on the details of the offer, including milestone payments. The company's conference presentation is also generating buzz, as investors hope for updates on potential deals. A potential short squeeze is also part of the discussion due to the ticker's high short interest.

Hour Loop, Inc. is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market and sell products. It operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The company was founded by Sam Lai and Sau Kuen Yu in 2013 and is headquartered in Redmond, WA.

Hour Loop Inc

HOUR is trending due to significant volatility, marked by rapid price swings and trading halts, leading to community discussions about potential pump-and-dump schemes and coordinated efforts. Traders are actively debating entry and exit strategies amidst the stock's high volume and low float, while some express concerns about the lack of news driving the movement. The stock's behavior is also being compared to other recent low float runners.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending amid speculation surrounding a potential Dogecoin ETF, with the community buzzing about possible approval and its impact. Some traders point to technical indicators suggesting bullish momentum, while others are discussing the potential for Dogecoin to reach new all-time highs. The conversation also includes debate around Dogecoin's utility and its future in the broader crypto market.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar ($GSAT) is trending amid community excitement surrounding the potential valuation of its spectrum assets, drawing comparisons to recent deals made by competitors like EchoStar. Speculation is increasing about potential acquisitions, partnerships with major players like Apple, Verizon, or SpaceX, and the impact of upcoming catalysts such as India spectrum approval and news from the Apple event.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Telomir Pharmaceuticals surged during after-hours trading Thursday following the announcement of early laboratory data from research conducted on progeria-affected cells from a young patient.The stock closed at $1.21 on Thursday, then surged 138.8% after hours to $2.89 following the preclinical data.The rare disease, Hutchinson-Gilford Progeria Syndrome (HGPS), emerges from one gene mutation which triggers the accumulation of progerin within the body. The disease affects fewer than 30 children in the U.S.Most start showing symptoms like growth delays and heart problems by age two, and many don’t live past their early teens.&nbsp;The only approved drug, Zokinvy, can add a few years to their lives but doesn’t stop the damage or undo what’s already happened.In the new study, conducted by Smart Assays using cells provided by the Progeria Research Foundation, Telomir-1 improved cell survival in a dose-dependent manner, even under stress conditions.&nbsp;It also reduced levels of reactive oxygen species, a marker of oxidative damage, and corrected iron-induced calcium overload linked to mitochondrial dysfunction.The company stated that these results, observed in actual patient-derived cells, demonstrate that Telomir-1 not only protects cells but also restores critical biological functions.&nbsp;Telomir-1 is designed to regulate metal ions, reduce oxidative stress, restore mitochondrial health, extend telomeres, reverse muscle loss, and reset age-related DNA methylation patterns.CEO Erez Aminov said that the findings support broader potential beyond progeria, including neurodegeneration and metabolic disorders.The results also validated prior preclinical work in animal models, where Telomir-1 extended lifespan and reversed age phenotypes in zebrafish and C. elegans models of Werner syndrome, an adult form of progeria.&nbsp;Telomir is completing IND-enabling studies and is due to meet with the U.S. Food and Drug Administration (FDA) to discuss potential regulatory pathways, including orphan drug designation.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.The Telomir stream on Stocktwits saw a nearly 30% increase in watcher count over the past 24 hours, leading up to late Thursday, with the 24-hour message volume surging up by 8,600%.One user predicted a sharp move, saying Telomir could hit $8–$10 in post-market trading before “a crazy rocket” at the open toward $20 or higher.&nbsp;<stembedurl>https://stocktwits.com/time4themoon/message/621444979</stembedurl>Another user noted the stock’s momentum late in the session, and added that it was “seeing a nice bid going into the extended session close” with expectations to be “jamming in premarket.”<stembedurl>https://stocktwits.com/phijammaslamma/message/621430208</stembedurl><a href="https://stocktwits.com/symbol/TELO">Telomir’s stock</a> has declined 70.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Telomir Pharmaceuticals (TELO) said early lab results showed its drug candidate helped restore damaged cells from a child with progeria. (Photo credit: Getty Images)

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains

The early lab study used cells from a child with progeria and showed improvements in cell survival, reduced oxidative stress, and restored mitochondrial function, which are key signs of aging. 

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage in Progeria Cells; Retail Eyes Bigger Gains

Equity

Telomir Pharmaceuticals' anti-aging expert to present pre-clinical data

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Telomir's pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase...

UPDATE   Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused on...

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused...

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1  to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells The New York Times...

Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate's Potential in DNA Age Reversal Science

Continued work with computer-aided pre-clinical testing shows Telomir-1 has the potential to extend DNA telomeres to reverse age-related conditionsBALTIMORE, March 14, 2024 (GLOBE NEWSWIRE...

Telomir Pharmaceuticals presents preclinical data for Telomir-1

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference

Together with its partner, Frontage Laboratories, Telomir's poster focused on pre-clinical data demonstrating Telomir-1's ability to elongate telomere caps on human stem cells, targeting age-related...

Telomir Pharmaceuticals announces Roizen to increase role at company

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm’s initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded by Christopher C. Chapman Jr. on August 26, 2021 and is headquartered in Miami, FL.

Current Price	$1.21
Prev Close	$1.24
Open	$1.23
Dividend Yield	0.00%
50-Day Moving Average	$1.55
Beta	0.82
Avg. Volume	4.02M
PE Ratio	-2.29

52-Week High	$8.40
52-Week Low	$1.12
Market Capitalization	$40.03M
EPS (Annual)	-$0.5597
Price to Book	78.63
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TELO
Telomir Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest TELO News

TELO Telomir Pharmaceuticals Inc